Johanne Rozema1,2, Christiaan L Slim3, Nic J G M Veeger4,5, Robby E Kibbelaar6, Harry de Wit3, Eric N van Roon1,2, Mels Hoogendoorn7. 1. Unit of Pharmacotherapy, Epidemiology and Economics, Department of Pharmacy, University of Groningen, Groningen, the Netherlands. 2. Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, Leeuwarden, the Netherlands. 3. Certe Medical Diagnostics and Advice, Medical Centre Leeuwarden, Leeuwarden, the Netherlands. 4. Science Bureau, Medical Centre Leeuwarden, Leeuwarden, the Netherlands. 5. Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands. 6. Pathologie Friesland, Leeuwarden, the Netherlands. 7. Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.
Abstract
BACKGROUND: Alloimmunisation against blood products is an adverse event, causing time-consuming compatibility testing. Current literature has not yet identified the influence of treatment on the risk of alloimmunisation in patients with myelodysplastic syndromes (MDS). MATERIALS AND METHODS: An observational, population-based study, using the HemoBase registry, was performed including all transfused patients who were diagnosed with MDS between 2005 and 2017 in Friesland, a province in the Netherlands. Information about transfusion dates, types, and treatment regimens was collected from the health records. Blood products were matched for ABO and Rhesus D. The effect of disease-modifying treatment was estimated with incidence rates and a Cox time-dependent analysis. RESULTS: 233 patients were included in this study, with a median follow-up of 13.0 months. Alloimmunisation occurred in 21 patients (9.0%) and predominantly occurred early in follow-up. Three (5%) and 18 (11%) alloimmunisation events occurred in patients with and without disease-modifying treatment, respectively. The hazard ratio for alloimmunisation without treatment compared to during treatment was 2.7 (95% CI: 0.35-20.0), with incidence rates of 7.18 and 2.41 per 100 patient-years, respectively. DISCUSSION: In a non-selected real-world population of MDS patients receiving blood transfusions, the percentage of patients with alloimmunisation was below 10%. The results of this study support the hypothesis that disease-modifying treatment affects the ability of the immune system to mount an antibody response to non-self blood group antigens.
BACKGROUND: Alloimmunisation against blood products is an adverse event, causing time-consuming compatibility testing. Current literature has not yet identified the influence of treatment on the risk of alloimmunisation in patients with myelodysplastic syndromes (MDS). MATERIALS AND METHODS: An observational, population-based study, using the HemoBase registry, was performed including all transfused patients who were diagnosed with MDS between 2005 and 2017 in Friesland, a province in the Netherlands. Information about transfusion dates, types, and treatment regimens was collected from the health records. Blood products were matched for ABO and Rhesus D. The effect of disease-modifying treatment was estimated with incidence rates and a Cox time-dependent analysis. RESULTS: 233 patients were included in this study, with a median follow-up of 13.0 months. Alloimmunisation occurred in 21 patients (9.0%) and predominantly occurred early in follow-up. Three (5%) and 18 (11%) alloimmunisation events occurred in patients with and without disease-modifying treatment, respectively. The hazard ratio for alloimmunisation without treatment compared to during treatment was 2.7 (95% CI: 0.35-20.0), with incidence rates of 7.18 and 2.41 per 100 patient-years, respectively. DISCUSSION: In a non-selected real-world population of MDS patients receiving blood transfusions, the percentage of patients with alloimmunisation was below 10%. The results of this study support the hypothesis that disease-modifying treatment affects the ability of the immune system to mount an antibody response to non-self blood group antigens.
Authors: Rakchha Chhetri; Li Yan A Wee; Romi Sinha; Monika M Kutyna; Anh Pham; Helen Stathopoulos; Lakshmi Nath; Shriram V Nath; Nicholas Wickham; Tim Hughes; Deepak Singhal; David J Roxby; Devendra K Hiwase Journal: Haematologica Date: 2019-02-28 Impact factor: 9.941
Authors: C Milkins; J Berryman; C Cantwell; C Elliott; R Haggas; J Jones; M Rowley; M Williams; N Win Journal: Transfus Med Date: 2012-12-06 Impact factor: 2.019
Authors: Gláucia A S Guelsin; Camila Rodrigues; Jeane E L Visentainer; Paula De Melo Campos; Fabíola Traina; Simone C O Gilli; Sara T O Saad; Lilian Castilho Journal: Blood Transfus Date: 2014-06-12 Impact factor: 3.443
Authors: Dorothea Evers; Rutger A Middelburg; Masja de Haas; Saurabh Zalpuri; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C Péquériaux; Francisca Hudig; Henk Schonewille; Jaap Jan Zwaginga; Johanna G van der Bom Journal: Lancet Haematol Date: 2016-05-09 Impact factor: 18.959
Authors: Deepak Singhal; Monika M Kutyna; Rakchha Chhetri; Li Yan A Wee; Sophia Hague; Lakshmi Nath; Shriram V Nath; Romi Sinha; Nicholas Wickham; Ian D Lewis; David M Ross; Peter G Bardy; Luen Bik To; John Reynolds; Erica M Wood; David J Roxby; Devendra K Hiwase Journal: Haematologica Date: 2017-10-05 Impact factor: 9.941
Authors: Johanne Rozema; Eric N van Roon; Robby E Kibbelaar; Nic J G M Veeger; Christiaan L Slim; Harry de Wit; Mels Hoogendoorn Journal: Transfusion Date: 2021-09-03 Impact factor: 3.337
Authors: Johanne Rozema; Mels Hoogendoorn; Iris Potma; Inge Ten Seldam; Nic J G M Veeger; Robby E Kibbelaar; Arjan A van de Loosdrecht; Eric N van Roon Journal: EJHaem Date: 2022-03-25